a quote from this article and my thoughts on it..
"If you look at things by therapeutic area, oncology has the roughest row to hoe with over 93% failure. Its failure rate is still over 50% in Phase III, which is particularly hair-raising. "
I dont think this is only because oncology is "harder". A lot of it has to do with what Dew has pointed out on here. There are a ton of compounds in development (compared to other disease areas), and a lot of them are very low quality programs. Companies tend to do less chasing in other areas, and dont force as many low quality compounds into ph 3
News 
Market Data 
Discover 
